EUCTR2015-003213-18-GB进行中（未招募）1 期
A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) - ACCEPT
niversity Hospital Southampton NHS Foundation Trust0 个研究点目标入组 39 人开始时间: 2016年12月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed DLBCL, expressing CD20. Sufficient diagnostic material should be available to forward to a central laboratory for gene expression profiling and pathology review
- •2. Measurable disease of at least 15mm
- •3. Not previously treated for lymphoma and fit enough to receive combination chemoimmunotherapy with curative intent
- •4. Stage IAX (bulk defined as lymph node diameter >10cm) to stage IV disease and deemed to require a full course of chemotherapy. Patients with non-bulky IE disease are not eligible
- •5. ECOG performance status 0-2 or 3 if this is directly attributable to lymphoma
- •6. Adequate bone marrow function with platelets > 100x109/L; neutrophils > 1.0x109/L at study entry, unless lower figures are attributable to lymphoma
- •7. Measured or calculated creatinine clearance > 30mls/min, (calculated using the formula of Cockcroft and Gault [(140-Age) x Mass (kg)x(1.04 (for women)or 1.23 (for men))/Serum Creatinine (umolL)]
- •8. Serum bilirubin < 35µmol/L and transaminases < 2.5x upper limit of normal at time of study entry
- •9. Cardiac function sufficient to tolerate 300mg/m2 of doxorubicin. A pre-treatment echocardiogram or MUGA is required to establish baseline LVEF equal to or greater than 55%
- •10. No concurrent uncontrolled medical condition
- •11. Life expectancy > 3 months
- •12. Aged 16 years or above
- •13. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
- •14. Ability to understand the purpose and risks of the study and provide signed and dated informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Previous history of treated or untreated indolent lymphoma. However newly diagnosed patients with DLBCL who are found to also have small cell infiltration of the bone marrow or other diagnostic material (discordant lymphoma) will be eligible
- •2. Patients who have received immunisation with a live vaccine within four weeks prior to enrolment will be ineligible
- •3. Diagnosis of primary mediastinal lymphoma
- •4. Diagnosis of primary Central Nervous System lymphoma.
- •5. History of stroke or intracranial haemorrhage in preceding 6 months
- •6. History of bleeding diathesis (eg. haemophilia, von Willebrand disease)
- •7. Requires or receiving anticoagulation with warfarin or equivalent antagonists (eg. phenprocoumon) within 7 days of first dose of acalabrutinib. However patients using therapeutic low molecule weight heparin or low dose aspirin will be eligible
- •8. Prior exposure to a BCR inhibitor(eg. BtK inhibitors, phosphoinositide-3 kinase (PI3K), or SyK inhibitors) or BCL-2 inhibitor (eg. ABT-199)
- •9. Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer
- •10. Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors who switch to short-acting H2-receptor antagonists or antacids are eligible for enrolment into this study.
- •11. Uncontrolled systemic infection
- •12. Major surgery in the preceding 4 weeks of first dose of study drug. If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug
- •13. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) > 480 msec at screening.
- •14. Serological positivity for Hepatitis B, C, or known HIV infection. As per standard of care, prior to initiation of immunochemotherapy, the results of hepatitis serology should be known prior to commencement of therapy.
- •-Positive test results for chronic HBV infection (defined as positive HBsAg serology) will not be eligible. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) will not be eligible. Patients who have protective titres of hepatitis B surface antibody (HBsAb) after vaccination will be eligible.
- •-Positive test results for hepatitis C virus (HCV) antibody serology will not be eligible.
- •15. Women who are sexually active and can bear children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of acalabrutinib. Highly effective forms of contraception are defined in Section 4.7
- •16. Breastfeeding or pregnant
- •17. Men who are sexually active and can potentially father children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of acalabrutinib. Highly effective forms of contraception are defined in Section 4.7
- •18. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of study drug.
- •19. Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent
- •20. Prior malignancy (other than DLBCL), exc
研究者
相似试验
进行中（未招募）
1 期
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphomaMarginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapyMedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004396-38-ATIELSG - International Extranodal Lymphoma Study Group24
进行中（未招募）
1 期
Study of acalabrutinib and tafasitamab in patients with marginal zone lymphomaMarginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapyMedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004396-38-ITIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP24
招募中
1 期
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphomaMarginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapyMedDRA version: 20.0Level: PTClassification code: 10076596Term: Marginal zone lymphoma Class: 100000004864CTIS2024-514122-23-00Association International Extranodal Lymphoma Study Group (IELSG)24
进行中（未招募）
1 期
A study of Acalabrutinib alone, or in combination with Rituximab and Lenalidomide for subjects with B-cell Non Hodgkin LymphomaB-cell Non-Hodgkin LymphomaMedDRA version: 21.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000111-84-ITACERTA PHARMA BV120
招募中
不适用
Acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphomaKCT0003724Seoul National University Hospital66